Verastem announced that the first patient has been dosed in a Phase 1/2 trial in China, conducted by GenFleet Therapeutics, evaluating GFH375/VS-7375, a KRAS G12D inhibitor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem price target lowered to $18 from $34 at Truist
- Verastem to be added to the Russell 3000 & Microcap Indexes effective July 1
- Verastem Updates Corporate Presentation with Latest Insights
- Verastem partner GenFleet says China’s NMPA approved clinical trial application
- Verastem price target lowered to $20 from $34 at Alliance Global Partners